Ignite Creation Date:
2024-05-05 @ 7:34 PM
Last Modification Date:
2024-10-26 @ 9:51 AM
Study NCT ID:
NCT00697931
Status:
COMPLETED
Last Update Posted:
2008-06-16
First Post:
2008-06-12
Brief Title:
Immunogenicity and Reactogenicity of MPL Adjuvanted Recombinant Hepatitis B- Vaccine and Engerix-B in Adult Non-Responders
Sponsor:
GlaxoSmithKline
Organization:
GlaxoSmithKline
Study Overview
Official Title:
Study to Compare the Immunogenicity and Reactogenicity of GSK Biologicals Previously SmithKline Beecham Biologicals MPL-Adjuvanted Recombinant Hepatitis B Vaccine With That of Engerix-B in an Adult Non-Responder Population
Status:
COMPLETED
Status Verified Date:
2008-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to compare the immunogenicity and reactogenicity of the adjuvanted recombinant hepatitis B vaccine with that of Engerix-B when both are injected according to a three dose schedule 0 1 6 months in an adult non-responder population
Detailed Description:
At the time of conduct of this study the sponsor GlaxoSmithKline was known by its former name SmithKline Beecham
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None